Baltimore pharmaceutical firm Profectus BioSciences Inc. has received a $9.5 million grant from the Department of Defense for a phase 1 clinical trial of its Ebola vaccine. T
he award is Profectus’ fourth this year — all for work developing and manufacturing Ebola vaccines. The new grant brings the company’s total funding up to at least $49.8 million.
{iframe}http://www.bizjournals.com/baltimore/news/2014/10/31/profectus-biosciences-gets-another-9-5-million-for.html{/iframe}